RADIOPHARM THERANOSTICS LIMITED - Announcements

8.82%

3.1¢

Market Cap $73.31M

Healthcare Biotechnology

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics... Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

RAD	Ga68-Integrin (RAD301) selected for presentation at EANM		27/09/22	141.11KB	Share
RAD	Pivalate phase II data to be presented at October conference		21/09/22	111.69KB	Share
RAD	Notification regarding unquoted securities - RAD		20/09/22	31.95KB	Share
RAD	RAD and SHINE Supply Agreement for Cancer-Fighting Isotope		20/09/22	157.67KB	Share
RAD	FDA grants pediatric disease designation for DUNP19-revised		16/09/22	165.37KB	Share
RAD	FDA grants rare pediatric disease designation for DUNP19	PRICE SENSITIVE	16/09/22	162.46KB	Share
RAD	JV with MD Anderson to develop novel radiopharmaceuticals		14/09/22	189.4KB	Share
RAD	FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma	PRICE SENSITIVE	09/09/22	158.06KB	Share
RAD	Appendix 4E and Preliminary Final Report - unaudited		05/09/22	190.09KB	Share
RAD	Application for quotation of securities - RAD		01/09/22	24.36KB	Share
RAD	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	31/08/22	265.37KB	Share
RAD	Notification of Release of Shares from Escrow		23/08/22	144.52KB	Share
RAD	Strategic agreements with Lantheus and NanoMab		04/08/22	238KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	2.77MB	Share
RAD	GenesisCare agreement extended to prostate cancer trial		01/07/22	111.98KB	Share
RAD	Dr Susann Brady-Kalnay added to Scientific Advisory Board		21/06/22	113.41KB	Share
RAD	Investor webinar - RAD adds brain tumor technology		15/06/22	154.76KB	Share
RAD	Supply agreement with Isotopia for Lutetium-177		14/06/22	204.21KB	Share
RAD	Investor Presentation		09/06/22	2.17MB	Share
RAD	RAD adds Brain Tumor Technology to Portfolio		09/06/22	216.68KB	Share
RAD	Initial Director's Interest Notice - LA		06/06/22	244.93KB	Share
RAD	RAD Appoints Dr Leila Alland as Non-Executive Director		06/06/22	112.28KB	Share
RAD	Industry leader Vittorio Puppo appointed COO		01/06/22	113.42KB	Share
RAD	Notification regarding unquoted securities - RAD		30/05/22	31.54KB	Share
RAD	Notice Under Section 708A		27/05/22	171.32KB	Share
RAD	Application for quotation of securities - RAD		27/05/22	26.33KB	Share
RAD	RAD presentation to Bioshares Biotech Summit		12/05/22	2.21MB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	2.39MB	Share
RAD	Virtual investor conference presentation 2 May 2022		28/04/22	109.89KB	Share
RAD	Change of Director's Interest Notice - PH		14/04/22	172.99KB	Share
RAD	Change of Director's Interest Notice - IT		13/04/22	173.39KB	Share
RAD	Change of Director's Interest Notice - RC		12/04/22	186.41KB	Share
RAD	RAD Dual Action Antibody Investor Deck		04/04/22	2.08MB	Share
RAD	RAD Licenses UCLA Dual Action Antibody	PRICE SENSITIVE	04/04/22	281.46KB	Share
RAD	Change of Director's Interest Notice - HL		31/03/22	172.51KB	Share
RAD	Investor Presentation		28/03/22	1MB	Share
RAD	LOI with GenesisCare to start first trial in Australia	PRICE SENSITIVE	23/03/22	138.89KB	Share
RAD	Change of Director's Interest Notice - IT		04/03/22	154.44KB	Share
RAD	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	1.42MB	Share
RAD	Change in substantial holding NT		25/02/22	492.5KB	Share
RAD	Radiopharm and Terrapower supplementary announcement		10/02/22	137.85KB	Share
RAD	Initial Director's Interest Notice - HL		04/02/22	245.08KB	Share
RAD	Hester Larkin appointed as Non-Executive Director		02/02/22	177.04KB	Share
RAD	Director Appointment/Resignation		02/02/22	177.04KB	Share
RAD	Radiopharm and TerraPower sign Actinium 225 agreement	PRICE SENSITIVE	01/02/22	194.54KB	Share
RAD	Application for quotation of securities - RAD		27/01/22	24.81KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/01/22	1.13MB	Share
RAD	Proposed issue of securities - RAD		25/01/22	24.65KB	Share
RAD	RAD acquires IP Ownership of Radiopharmaceutical Nanobodies	PRICE SENSITIVE	24/01/22	165.54KB	Share
RAD	Change of Director's Interest Notice - RC		11/01/22	235.91KB	Share
RAD	RAD to present at Biotech Showcase		10/01/22	110.6KB	Share
RAD	Expansion of RAD management team		20/12/21	115.95KB	Share
RAD	Completion of Phase 1 imaging study in breast cancer		17/12/21	190.68KB	Share
RAD	Change of Director's Interest Notice - IT		13/12/21	153KB	Share
RAD	Change of Director's Interest Notice - PH		10/12/21	200.22KB	Share
RAD	Letter to shareholders		10/12/21	111.91KB	Share
RAD	Change of Director's Interest Notice - RC		09/12/21	201.08KB	Share
RAD	RAD Integrins technology featured in Cancers journal	PRICE SENSITIVE	08/12/21	226.83KB	Share
RAD	Dr Sara Hurvitz appointed to Scientific Advisory Board		06/12/21	111.96KB	Share
RAD	Change of Director's Interest Notice - IT		30/11/21	153.17KB	Share
RAD	Becoming a substantial holder - NT		30/11/21	112.25KB	Share
RAD	Change of Director's Interest Notice - PH		29/11/21	175.96KB	Share
RAD	Investor Presentation		29/11/21	2.71MB	Share
RAD	Becoming a substantial holder - PH		26/11/21	235.91KB	Share
RAD	Initial Director's Interest Notice - PH		26/11/21	164.04KB	Share
RAD	Initial Director's Interest Notice - RC		26/11/21	163.84KB	Share
RAD	Initial Director's Interest Notice - MB		26/11/21	167.52KB	Share
RAD	Initial Director's Interest Notice - IT		26/11/21	164.48KB	Share
RAD	Radiopharm Theranostics Commences Trading on the ASX		25/11/21	234.45KB	Share
RAD	Pre-quotation Disclosure		23/11/21	173.82KB	Share
RAD	Top 20 Shareholders		23/11/21	74.69KB	Share
RAD	Distribution Schedule		23/11/21	63.26KB	Share
RAD	Securities Trading Policy		23/11/21	249.62KB	Share
RAD	Omnibus Incentive Plan		23/11/21	272.01KB	Share
RAD	Annual Report 30 June 2021		23/11/21	411.3KB	Share
RAD	Constitution		23/11/21	410.19KB	Share
RAD	Supplementary Prospectus		23/11/21	277.88KB	Share
RAD	Prospectus		23/11/21	5.02MB	Share
RAD	Appendix 1A and Information Form and Checklist		23/11/21	436.73KB	Share
RAD	Admission and Quotation		23/11/21	449.95KB	Share

RAD Ga68-Integrin (RAD301) selected for presentation at EANM
27/09/22		141.11KB	Share
RAD Pivalate phase II data to be presented at October conference
21/09/22		111.69KB	Share
RAD Notification regarding unquoted securities - RAD
20/09/22		31.95KB	Share
RAD RAD and SHINE Supply Agreement for Cancer-Fighting Isotope
20/09/22		157.67KB	Share
RAD FDA grants pediatric disease designation for DUNP19-revised
16/09/22		165.37KB	Share
RAD FDA grants rare pediatric disease designation for DUNP19
16/09/22	PRICE SENSITIVE	162.46KB	Share
RAD JV with MD Anderson to develop novel radiopharmaceuticals
14/09/22		189.4KB	Share
RAD FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma
09/09/22	PRICE SENSITIVE	158.06KB	Share
RAD Appendix 4E and Preliminary Final Report - unaudited
05/09/22		190.09KB	Share
RAD Application for quotation of securities - RAD
01/09/22		24.36KB	Share
RAD Appendix 4E and Preliminary Final Report
31/08/22	PRICE SENSITIVE	265.37KB	Share
RAD Notification of Release of Shares from Escrow
23/08/22		144.52KB	Share
RAD Strategic agreements with Lantheus and NanoMab
04/08/22		238KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	2.77MB	Share
RAD GenesisCare agreement extended to prostate cancer trial
01/07/22		111.98KB	Share
RAD Dr Susann Brady-Kalnay added to Scientific Advisory Board
21/06/22		113.41KB	Share
RAD Investor webinar - RAD adds brain tumor technology
15/06/22		154.76KB	Share
RAD Supply agreement with Isotopia for Lutetium-177
14/06/22		204.21KB	Share
RAD Investor Presentation
09/06/22		2.17MB	Share
RAD RAD adds Brain Tumor Technology to Portfolio
09/06/22		216.68KB	Share
RAD Initial Director's Interest Notice - LA
06/06/22		244.93KB	Share
RAD RAD Appoints Dr Leila Alland as Non-Executive Director
06/06/22		112.28KB	Share
RAD Industry leader Vittorio Puppo appointed COO
01/06/22		113.42KB	Share
RAD Notification regarding unquoted securities - RAD
30/05/22		31.54KB	Share
RAD Notice Under Section 708A
27/05/22		171.32KB	Share
RAD Application for quotation of securities - RAD
27/05/22		26.33KB	Share
RAD RAD presentation to Bioshares Biotech Summit
12/05/22		2.21MB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	2.39MB	Share
RAD Virtual investor conference presentation 2 May 2022
28/04/22		109.89KB	Share
RAD Change of Director's Interest Notice - PH
14/04/22		172.99KB	Share
RAD Change of Director's Interest Notice - IT
13/04/22		173.39KB	Share
RAD Change of Director's Interest Notice - RC
12/04/22		186.41KB	Share
RAD RAD Dual Action Antibody Investor Deck
04/04/22		2.08MB	Share
RAD RAD Licenses UCLA Dual Action Antibody
04/04/22	PRICE SENSITIVE	281.46KB	Share
RAD Change of Director's Interest Notice - HL
31/03/22		172.51KB	Share
RAD Investor Presentation
28/03/22		1MB	Share
RAD LOI with GenesisCare to start first trial in Australia
23/03/22	PRICE SENSITIVE	138.89KB	Share
RAD Change of Director's Interest Notice - IT
04/03/22		154.44KB	Share
RAD Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	1.42MB	Share
RAD Change in substantial holding NT
25/02/22		492.5KB	Share
RAD Radiopharm and Terrapower supplementary announcement
10/02/22		137.85KB	Share
RAD Initial Director's Interest Notice - HL
04/02/22		245.08KB	Share
RAD Hester Larkin appointed as Non-Executive Director
02/02/22		177.04KB	Share
RAD Director Appointment/Resignation
02/02/22		177.04KB	Share
RAD Radiopharm and TerraPower sign Actinium 225 agreement
01/02/22	PRICE SENSITIVE	194.54KB	Share
RAD Application for quotation of securities - RAD
27/01/22		24.81KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
25/01/22	PRICE SENSITIVE	1.13MB	Share
RAD Proposed issue of securities - RAD
25/01/22		24.65KB	Share
RAD RAD acquires IP Ownership of Radiopharmaceutical Nanobodies
24/01/22	PRICE SENSITIVE	165.54KB	Share
RAD Change of Director's Interest Notice - RC
11/01/22		235.91KB	Share
RAD RAD to present at Biotech Showcase
10/01/22		110.6KB	Share
RAD Expansion of RAD management team
20/12/21		115.95KB	Share
RAD Completion of Phase 1 imaging study in breast cancer
17/12/21		190.68KB	Share
RAD Change of Director's Interest Notice - IT
13/12/21		153KB	Share
RAD Change of Director's Interest Notice - PH
10/12/21		200.22KB	Share
RAD Letter to shareholders
10/12/21		111.91KB	Share
RAD Change of Director's Interest Notice - RC
09/12/21		201.08KB	Share
RAD RAD Integrins technology featured in Cancers journal
08/12/21	PRICE SENSITIVE	226.83KB	Share
RAD Dr Sara Hurvitz appointed to Scientific Advisory Board
06/12/21		111.96KB	Share
RAD Change of Director's Interest Notice - IT
30/11/21		153.17KB	Share
RAD Becoming a substantial holder - NT
30/11/21		112.25KB	Share
RAD Change of Director's Interest Notice - PH
29/11/21		175.96KB	Share
RAD Investor Presentation
29/11/21		2.71MB	Share
RAD Becoming a substantial holder - PH
26/11/21		235.91KB	Share
RAD Initial Director's Interest Notice - PH
26/11/21		164.04KB	Share
RAD Initial Director's Interest Notice - RC
26/11/21		163.84KB	Share
RAD Initial Director's Interest Notice - MB
26/11/21		167.52KB	Share
RAD Initial Director's Interest Notice - IT
26/11/21		164.48KB	Share
RAD Radiopharm Theranostics Commences Trading on the ASX
25/11/21		234.45KB	Share
RAD Pre-quotation Disclosure
23/11/21		173.82KB	Share
RAD Top 20 Shareholders
23/11/21		74.69KB	Share
RAD Distribution Schedule
23/11/21		63.26KB	Share
RAD Securities Trading Policy
23/11/21		249.62KB	Share
RAD Omnibus Incentive Plan
23/11/21		272.01KB	Share
RAD Annual Report 30 June 2021
23/11/21		411.3KB	Share
RAD Constitution
23/11/21		410.19KB	Share
RAD Supplementary Prospectus
23/11/21		277.88KB	Share
RAD Prospectus
23/11/21		5.02MB	Share
RAD Appendix 1A and Information Form and Checklist
23/11/21		436.73KB	Share
RAD Admission and Quotation
23/11/21		449.95KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 3.1¢		Change -0.003(8.82%)		Mkt cap ! $73.31M

Open	High	Low	Value	Volume
3.4¢	3.4¢	3.1¢	$58.95K	1.821M

Buyers (Bids)

No.	Vol.	Price($)
4	783888	3.1¢

Sellers (Offers)

Price($)	Vol.	No.
3.2¢	870662	1

View Market Depth

No.	Vol.	Price($)
3	683888	0.031
3	1230000	0.030
6	505133	0.029
3	649718	0.028
5	1761111	0.027

Price($)	Vol.	No.
0.032	870662	1
0.033	325000	1
0.034	1090328	2
0.035	2373494	10
0.036	1165378	3

Last trade - 16.10pm 19/09/2025 (20 minute delay)

RAD (ASX) Chart

RADIOPHARM THERANOSTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available